AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05130541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Care
Description: Usual Care
Study NCT05130541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Usual Care
Study NCT02454816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single HIV RDT and single syphilis RDT
Description: It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
Study NCT02454816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual HIV/syphilis RDT
Description: It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hib-IPV
Study NCT02445157 — intervention group
Intervention type: OTHER
Intervention: 4MGS
Description: Measurement of usual gait speed over 4 metres (metres/second)
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PC7
Description: One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Study NCT00310856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella
Study NCT04661189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
Study NCT04661189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DN4 test
Description: The DN4 test was used to evaluate neuropathic pain.
Study NCT04341116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ003234
Description: patients receive a single infusion
Study NCT04341116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients receive a single infusion
Study NCT03928080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bleeding on brushing
Description: Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
Study NCT00627484 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: NOTE: the surgery is not paid for by the study
Study NCT00627484 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric banding
Description: NOTE: the surgery is not paid for by the study
Study NCT00627484 — intervention group
Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: NOTE: the surgery is not paid for by the study
Study NCT00627484 — intervention group
Intervention type: BEHAVIORAL
Intervention: Very low calorie diet
Description: Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
Study NCT02246179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
Study NCT02246179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AFXL
Description: Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
Study NCT02246179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes
Study NCT02246179 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: AHES
Description: Topical application at test region 1 and 3 under occlusion for 10 minutes
Study NCT02246179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: Topical application at test region 2 and 4 under occlusion for 10 minutes
Study NCT02246179 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EMLA cream
Description: Topical application at test region 2 and 4 under occlusion for 10 minutes
Study NCT01289860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoids
Description: 475g of anthocyanidins in 300ml of blueberry drink.
Study NCT01289860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
Study NCT02739425 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sentimag Device
Description: The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
Study NCT03468686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral rTMS
Description: The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
Study NCT03468686 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
Study NCT03468686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral rTMS (High frequency)
Description: The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
Study NCT03691987 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Preprocessed thawed donor FMT
Description: Delivered as an enema using the same equipment and technique as X-ray of the colon
Study NCT03691987 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Preprocessed thawed autologous FMT
Description: Delivered as an enema using the same equipment and technique as X-ray of the colon
Study NCT01399775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implantation
Description: Immediately after tooth extraction, a dental implant is inserted
Study NCT01399775 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed implantation
Description: Four months after extraction, a dental implant is inserted and measurements are recorded.
Study NCT00936143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infliximab
Description: 100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
Study NCT00410735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg BID for 12 weeks
Study NCT00410735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranlukast hydrate
Description: 225 mg BID for 12 weeks
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference cigarette
Description: The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with carob bean extract
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with cocoa powder
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with fenugreek extract
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with fig juice
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with glycerol
Description: Based on reference cigarette with added ingredient
Study NCT04875481 — intervention group
Intervention type: OTHER
Intervention: Psychiatric diagnosis
Description: Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
Study NCT04875481 — intervention group
Intervention type: OTHER
Intervention: ASD diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study NCT01835951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Grouped Debriefing
Description: Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
Study NCT01835951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Individual Debriefing
Description: Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
Study NCT02015676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
Study NCT02015676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60 mg/m\^2 IV weekly; dose increased to 70 mg/m\^2, and subsequently 80 mg/m\^2, after 2 treatment cycles with no evidence of DLT until disease progression
Study NCT02015676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet
Description: 40 mg/m\^2 IV weekly; dose increased to 50 mg/m\^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with guaiacol
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with liquorice extract powder
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette plus I-menthol
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with propylene glycol
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with sorbitol
Description: Based on reference cigarette with added ingredient
Study NCT03272295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette with multiple ingredients
Description: Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
Study NCT01618162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study NCT01618162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously (under the skin) once daily.
Study NCT04603534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aged Simulation Suit
Description: The aged simulation suit (Sakamoto Model M716, Tokyo, Japan) will be worn by students. The simulation suit consist of a several items such as loads, a soft material band with Velcro, glasses, ear plugs, gloves, belts and a cane. All the items are need to simulate one's posture just like in elderly person. Small, medium and large sizes of suits are provided by the company thereby each suit is suitable for each student related to their wearing size. Prior to this study, a total of three sets of suits will be gathered. Then, each student will perform each pre-defined scenarios step by step after the suit is worn. During the activities no help or leading will be given to the students. However, one of the researchers will supervise the students during the activities so that to integrate a safe platform. In addition, each student will be informed that if he/she can terminate the activity whenever it is required.
Study NCT00542009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 100 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study NCT00542009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 50 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study NCT00542009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 25 mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study NCT03321396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium alginate mixed with calcium lactate
Description: The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel.
Study NCT00439868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WellbutrinXL
Description: WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
Study NCT00439868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching placebo tablets to WELLBUTRIN XL.
Study NCT00273312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone
Description: Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
Study NCT03386279 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: one single dose of 600 mg by mouth
Study NCT03386279 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin
Description: one single dose of 400 mg by mouth
Study NCT03386279 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one single dose by mouth
Study NCT03871595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: 3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water.
Study NCT03385928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Investigational product given within 2 hours of symptom onset
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DN4 test
Description: The DN4 test was used to evaluate neuropathic pain.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The SF 12 test
Description: The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HAD scale
Description: The anxiety/depression scale (HAD) was used to assess anxiety and depression.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study NCT02115945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analogue score
Description: Visual analogue score vas used to evaluate pain.
Study NCT02115945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral block
Study NCT02115945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural block
Study NCT03087461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and self-management
Description: The intervention will include aerobic exercise and self-management education using technology.
Study NCT04090788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dried bitter-gourd supplements
Description: intervention with 2.4g/d dried bitter-gourd supplements
Study NCT04090788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dried cucumber supplements
Description: reference intervention with 2.4g/d dried cucumber supplements
Study NCT03038152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo targeted axillary lymph node dissection
Study NCT03038152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Localization
Description: Undergo axillary lymph node localization
Study NCT03038152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device
Description: Receive Magseed via ultrasound guided injection
Study NCT02956720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: non-invasive body contouring procedure
Study NCT00565981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: orally, 40 mg/m2 d1-3 q4w, x4 cycles
Study NCT00565981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
Study NCT03888833 — intervention group
Intervention type: DEVICE
Intervention: ECMO
Description: ECMO installation
Study NCT02129374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct repair of pars defect
Description: Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
Study NCT01426256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
Study NCT03385928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo given within 2 hours of symptom onset
Study NCT01886898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infant formula
Description: infant formula
Study NCT01886898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: infant formula
Study NCT01886898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breastfeeding
Study NCT04650555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Powder
Description: Amorphous solid dispersion of genistein milled into a powder
Study NCT01077206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80mg daily versus 40mg daily, for 21 days.